How the protein vimentin affects healing after cataract surgery
Molecular function of extracellular vimentin in regulating the response to lens wounding
This work looks at whether vimentin released from lens cells changes how the lens heals after cataract surgery and could help prevent scarring that clouds vision.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11320809 on NIH RePORTER |
What this research studies
Using laboratory and ex vivo models that mimic the eye after cataract surgery, researchers study how vimentin is modified inside cells and released outside them. They examine the specific structural forms of extracellular vimentin and how it binds to lens cells to promote fibrotic scarring called posterior capsule opacification. The team will alter vimentin or block its interactions in lens tissue and cell models to see if those changes reduce fibrotic cell behavior. Results could point to new approaches—such as drugs or lens coatings—to prevent the cloudy scarring some people get after cataract extraction.
Who could benefit from this research
Good fit: People preparing for cataract surgery, those developing early posterior capsule opacification, or patients willing to donate lens tissue for research would be the most relevant candidates.
Not a fit: People without cataract-related lens injury or those seeking care for unrelated eye conditions (for example primary retinal diseases or glaucoma not involving lens fibrosis) are unlikely to directly benefit.
Why it matters
Potential benefit: If successful, this work could lead to treatments or implant coatings that reduce scarring and help preserve clearer vision after cataract surgery.
How similar studies have performed: Previous laboratory and ex vivo work has linked extracellular vimentin to wound responses and lens scarring, but moving these findings toward clinical treatments is still an emerging area.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Walker, Janice Lynn — Thomas Jefferson University
- Study coordinator: Walker, Janice Lynn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.